The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LQDA | +186.76% | +997.28% | +61.42% | +191% |
| S&P | +13% | +86.41% | +13.26% | +138% |
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.
Investors were obviously cheered by a round of insider buying.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $54.34M | 1121.7% |
| Gross Profit | $50.89M | 1878.0% |
| Gross Margin | 93.65% | 35.8% |
| Market Cap | $1.96B | 0.0% |
| Market Cap / Employee | $12.47M | 0.0% |
| Employees | 157 | 15.4% |
| Net Income | -$3.53M | 84.7% |
| EBITDA | $2.24M | 107.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $157.50M | -22.9% |
| Accounts Receivable | $35.96M | 755.8% |
| Inventory | 24.5 | 64463.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $142.70M | 9796.2% |
| Short Term Debt | $56.48M | 4421.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -46.08% | 19.5% |
| Return On Invested Capital | -75.63% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.68M | 60.2% |
| Operating Free Cash Flow | -$9.77M | 61.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | 16.16 | 21.38 | 128.55 | - | |
| Price to Sales | 71.15 | 88.82 | 55.19 | 28.36 | -43.47% |
| Price to Tangible Book Value | 17.79 | 24.89 | 237.12 | - | |
| Enterprise Value to EBITDA | -26.46 | -34.21 | -28.19 | 893.85 | -4493.10% |
| Return on Equity | -209.4% | -188.0% | -363.2% | -183.8% | 21.95% |
| Total Debt | $122.39M | $110.04M | $156.24M | $199.18M | 7301.78% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
